Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

FDA Approves Monthly Dosing of Rybrevant Faspro for NSCLC

2.

Cancer mortality continuing to decline, says report

3.

Schizophrenia patients are motivated by music therapy.

4.

Infection Burden High With Myeloma T-Cell Therapies

5.

Revolutionary Cancer Tx Could Transform Autoimmune Disease


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot